Short communicatio: Generation of the human metabolite piceatannol from the anticancer-Preventive agent resveratrol by bacterial cytochrome P450 BM3

Drug Metabolism and Disposition

Volumn 37, Issue 5, 2009, Pages 932-936

  Kim, Dong Hyun ^a   Ahn, Taeho ^a   Jung, Heung Chae ^b   Pan, Jae Gu ^b   Yun, Chul Ho ^a  

^a Chonnam National University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 BM3; DRUG METABOLITE; MUTANT PROTEIN; PICEATANNOL; RESVERATROL; 3,3',4,5'-TETRAHYDROXYSTILBENE; ANTINEOPLASTIC AGENT; BACTERIAL PROTEIN; CARBON MONOXIDE; FLAVOCYTOCHROME P450 BM3 MONOXYGENASES; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; STILBENE DERIVATIVE;

ARTICLE; BACILLUS MEGATERIUM; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG OXIDATION; ENZYME MECHANISM; ENZYME SUBSTRATE; ESCHERICHIA COLI; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROXYLATION; MASS FRAGMENTOGRAPHY; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; SYNTHESIS; WILD TYPE; CHEMISTRY; GENETICS; KINETICS; METABOLISM; MUTATION; OXIDATION REDUCTION REACTION; PHYSIOLOGY;

BACILLUS MEGATERIUM; BACTERIA (MICROORGANISMS);

ANTICARCINOGENIC AGENTS; BACTERIAL PROTEINS; CARBON MONOXIDE; CYTOCHROME P-450 ENZYME SYSTEM; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; HYDROXYLATION; KINETICS; MUTAGENESIS, SITE-DIRECTED; MUTATION; NADPH-FERRIHEMOPROTEIN REDUCTASE; OXIDATION-REDUCTION; STILBENES;

EID: 66449088011     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.026484     Document Type: Article

References (26)

1. Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR, and Kim AL (2007) Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 224:274-283.
2. Bernhardt R (2006) Cytochromes P450 as versatile biocatalysts. J Biotechnol 124:128-145.
3. Chun YJ, Kim S, Kim D, Lee SK, and Guengerich FP (2001) A new selective and potent
4. inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. Cancer Res 61:8164-8170.
5. Chun YJ, Kim MY, and Guengerich FP (1999) Resveratrol is a selective human cytochromeP450 1A1 inhibitor. Biochem Biophys Res Commun 262:20-24.
6. Di Nardo G, Fantuzzi A, Sideri A, Panicco P, Sassone C, Giunta C, and Gilardi G (2007)Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liverenzymes. J Biol Inorg Chem 12:313-323.
7. Fairman DA, Collins C, and Chapple S (2007) Progress curve analysis of CYP1A2 inhibition: amore informative approach to the assessment of mechanism-based inactivation? Drug MetabDispos 35:2159-2165.
8. Guengerich FP, Gillam EM, and Shimada T (1996) New applications of bacterial systems toproblems in toxicology. Crit Rev Toxicol 26:551-583.
9. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA, and Skaar TC (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151-159.
10. Kim DH, Kim KH, Kim DH, Liu KH, Jung HC, Pan JG, and Yun CH (2008a) Generation of human metabolites of 7-ethoxycoumarin by bacterial cytochrome P450 BM3. Drug Metab Dispos 36:2166-2170.
11. Kim YH, Kwon HS, Kim DH, Cho HJ, Lee HS, Jun JG, Park JH, and Kim JK (2008b)Piceatannol, a stilbene present in grapes, attenuates dextran sulfate sodium-induced colitis. Int Immunopharmacol 8:1695-1702.
12. Kundu JK and Surh YJ (2008) Cancer chemopreventive and therapeutic potential of resveratrol:mechanistic perspectives. Cancer Lett 269:243-261.
13. Li QS, Schwaneberg U, Fischer M, Schmitt J, Pleiss J, Lutz-Wahl S, and Schmid RD (2001)Rational evolution of a medium chain-specific cytochrome P-450 BM-3 variant. BiochimBiophys Acta 1545:114-121.
14. Mikstacka R, Rimando AM, Szalaty K, Stasik K, and Baer-Dubowska W (2006) Effect of natural analogues of trans-resveratrol on cytochromes P4501A2 and 2E1 catalytic activities. Xenobi-otica 36:269-285.
15. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. II.Solubilization, purification, and properties. J Biol Chem 239:2379-2385.
16. Otey CR, Bandara G, Lalonde J, Takahashi K, and Arnold FH (2005) Preparation of human metabolites of propranolol using laboratory-evolved bacterial cytochrome P450. BiotechnolBioeng 93:494-499.
17. Parikh A, Gillam EM, and Guengerich FP (1997) Drug metabolism by Escherichia coli expressing human cytochromes P450. Nat Biotechnol 15:784-788.
18. Pirola L and Frojdo S (2008) Resveratrol: one molecule, many targets. IUBMB Life 60:323-332.
19. Piver B, Fer M, Vitrac X, Merillon JM, Dreano Y, Berthou F, and Lucas D (2004) Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem Pharmacol 68:773-782.
20. Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, Ijaz T, Ruparelia KC, Lamb JH,Farmer PB, Stanley LA, et al. (2002) The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer 86:774-778.
21. Rushmore TH, Reider PJ, Slaughter D, Assang C, and Shou M (2000) Bioreactor systems in drug metabolism: Synthesis of cytochrome P450-generated metabolites. Metab Eng 2:115-125.
22. Stjernschantz E, van Vugt-Lussenburg BM, Bonifacio A, de Beer SB, van der Zwan G, Gooijer C, Commandeur JN, Vermeulen NP, and Oostenbrink C (2008) Structural rationalization of novel drug metabolizing mutants of cytochrome P450 BM3. Proteins 71:336-352.
23. Stottmeister U, Aurich A, Wilde H, Andersch J, Schmidt S, and Sicker D (2005) White biotechnology for green chemistry: fermentative 2-oxocarboxylic acids as novel building blocks for subsequent chemical syntheses. J Ind Microbiol Biotechnol 32:651-664.
24. Vail RB, Homann MJ, Hanna I, and Zaks A (2005) Preparative synthesis of drug metabolites using human cytochrome P450s 3A4, 2C9 and 1A2 with NADPH-P450 reductase expressed in Escherichia coli. J Ind Microbiol Biotechnol 32:67-74.
25. Yun CH, Kim KH, Kim DH, Jung HC, and Pan JG (2007) The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol 25:289-298.
26. Yun CH, Yim SK, Kim DH, and Ahn T (2006) Functional expression of human cytochrome P450 enzymes in Escherichia coli. Curr Drug Metab 7:411-429.